74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Amarin Corp PLC ADR
Closed
0.42
Overview
Share price change
24h
Min
0.41
Max
0.44
Income | -23M -49M |
|---|---|
Sales | 20M 62M |
EPS | -0.02 |
Profit margin | -78.031 |
Employees | 275 |
EBITDA | -13M -37M |
Recommendations | Neutral |
|---|---|
12 Months Forecast | +132.56% upside |
Next Earnings | 30 Apr 2025 |
|---|
Market Cap | -52M 186M |
|---|---|
Previous open | 0.42 |
Previous close | 0.42 |
Technical Score
By Trading Central
Confidence
Weak Bearish Evidence
Amarin Corp PLC ADR Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Amarin Corp PLC ADR Forecast
Price Target
By TipRanks
132.56% upside
12 Months Forecast
Average 1 USD 132.56%
High 1 USD
Low 1 USD
Based on 1 Wall Street analysts offering 12 month price targets forAmarin Corp PLC ADR - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Amarin Corp PLC ADR
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally to wholesalers and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.
